The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling.

Isabelle CooperCornelia B LandersdorferAshley Gordon St JohnAndis Graudins

Published in: SAGE open medicine (2018)

Given the reduced bioavailability of intranasal droperidol, Monte Carlo simulations suggested that it could potentially be used at a higher dose (2.5-5 mg) than currently used intravenously in clinical trials assessing the effectiveness in treatment of nausea, vomiting and migraine.

Keyphrases

monte carlo
clinical trial
chemotherapy induced
randomized controlled trial
systematic review
molecular dynamics
combination therapy
abdominal pain